BACKGROUND: Alcohol consumption is associated with a higher risk of colorectal cancer, but to the authors' knowledge its influence on survival after a diagnosis of colorectal cancer is unclear. The authors investigated associations between prediagnosis and postdiagnosis alcohol intake with mortality among survivors of colorectal cancer. METHODS: The authors identified 2458 men and women who were diagnosed with invasive, nonmetastatic colorectal cancer between 1992 (enrollment into the Cancer Prevention Study II Nutrition Cohort) and 2011. Alcohol consumption was self-reported at baseline and updated in 1997, 1999, 2003, and 2007. Postdiagnosis alcohol data were available for 1599 participants. RESULTS: Of the 2458 participants diagnosed with colorectal cancer, 1156 died during follow-up through 2012. Prediagnosis and postdiagnosis alcohol consumption were not found to be associated with all-cause mortality, except for an association between prediagnosis consumption of <2 drinks per day and a slightly lower risk of all-cause mortality (relative risk [RR], 0.86; 95% confidence interval [95% CI], 0.74-1.00) compared with never drinking. Alcohol use was generally not associated with colorectal cancer-specific mortality, although there was some suggestion of increased colorectal cancerspecific mortality with postdiagnosis drinking (RR, 1.27 [95% CI, 0.87-1.86] for current drinking of <2 drinks/day and RR, 1.44 [95% CI, 0.80-2.60] for current drinking of 2 drinks/day). CONCLUSIONS: The results of the current study do not support an association between alcohol consumption and all-cause mortality among individuals with nonmetastatic colorectal cancer. The association between postdiagnosis drinking and colorectal cancer-specific mortality should be examined in larger studies of individuals diagnosed with nonmetastatic colorectal cancer.
INTRODUCTION

Alcohol is classified as carcinogenic to humans by the US Department of Health and Human Services
1 and the International Agency for Research on Cancer. 2 Alcohol consumption accounts for 3.5% of all cancer deaths in the United States. 3 In 2013, among individuals aged 18 years, approximately 87% reported that they drank alcohol at some point in their life, and 56% drank alcohol within the past month. 4 The American Cancer Society Guidelines on Nutrition and Physical Activity for Cancer Prevention recommend that individuals who drink alcohol should limit their intake to 2 drinks per day for men and 1 drink per day for women. 5 There is substantial evidence that alcohol consumption is associated with a higher risk of colorectal cancer. According to a 2011 meta-analysis that summarized 61 epidemiologic studies, the relative risks (RRs) for 2 to 3 drinks per day and 4 drinks per day were 1.21 and 1.52, respectively. 6 To the best of our knowledge, whether alcohol intake has an impact on mortality among survivors of colorectal cancer is not clear. Nine cohort studies have examined alcohol consumption in relation to long-term, all-cause mortality after colorectal cancer diagnosis, [7] [8] [9] [10] [11] [12] [13] [14] [15] but only 4 of these studies examined colorectal cancer-specific mortality. 9, 10, 12, 13 Findings from these 9 studies were inconsistent: some studies suggested that light/moderate alcohol consumption compared with no alcohol consumption may be associated with lower all-cause or colorectal cancer-specific mortality, 9, 12, 13 whereas other studies reported largely null results 8, 11 or lower mortality only with red wine consumption. 7, 10, 15 It is interesting to note that the majority of the previous studies examined prediagnosis or lifetime alcohol consumption, whereas only one study 12 examined postdiagnosis alcohol consumption, which is more immediately translatable to cancer survivors but also may be more prone to bias. Furthermore, 3 studies 8, 11, 14 included individuals with metastatic colorectal cancer, which may bias the study results because those patients are more likely to die during study follow-up and are less likely to consume alcohol due to the severity of their disease. Given the dearth of evidence, the most recent American Cancer Society lifestyle guidelines for cancer survivors did not make specific recommendations regarding alcohol consumption, although they did recommend that patients undergoing chemotherapy or radiotherapy avoid alcohol to avoid impairment of liver function or oral mucositis. 16 It is important to expand this evidence base by evaluating the association between alcohol consumption and mortality for survivors of colorectal cancer, especially beyond the initial treatment phase for the disease. Observational studies are important for addressing this question because it is not feasible to conduct a randomized trial to test the effect of alcohol on mortality among cancer survivors.
In the current study, we report the associations between prediagnosis and postdiagnosis alcohol consumption and mortality from all-causes, colorectal cancerspecific, cardiovascular disease (CVD)-specific, and all other causes combined among patients diagnosed with invasive, nonmetastatic colorectal cancer during follow-up of a large prospective cohort in the United States.
MATERIALS AND METHODS
Study Cohort
This study comprised participants from the Cancer Prevention Study II (CPS-II) Nutrition Cohort, a prospective cohort study of cancer incidence and mortality among US men and women. 17 At the time of cohort enrollment in 1992 or 1993, approximately 184,000 men and women completed a 10-page, self-administered questionnaire that included questions concerning demographics, a detailed smoking and alcohol intake history, medical history, body size, diet, and other lifestyle factors. Participants completed follow-up questionnaires biennially starting in 1997 to update exposure information and to document new cancer diagnoses. The CPS-II Nutrition Cohort is approved by the Institutional Review Board of Emory University.
Of the 181,291 participants who had no history of colorectal cancer at the time of enrollment, we identified 4112 individuals who were diagnosed with colon or rectal cancer between their enrollment date in 1992 or 1993 and the end of incidence follow-up (June 30, 2011). Of these 4112 cases, 3232 were first self-reported on a follow-up questionnaire and subsequently verified through review of medical records (2353 cases) or by linkage with state cancer registries (879 cases); the remaining 880 cases were first identified through linkage to the National Death Index (NDI) as cancer deaths, 18 and 536 of these 880 cases subsequently were verified through linkage with state cancer registries.
Among the 4112 participants identified as having been diagnosed with colorectal cancer, the following exclusions were made: deaths identified through NDI that were not verified through medical records or cancer registries (344 participants); prevalent cancers (except for nonmelanoma skin cancer) at baseline (441 participants); implausible date of diagnosis (11 participants); missing or unknown stage of disease at the time of diagnosis (141 participants); TNM summary stage IV or distant Surveillance, Epidemiology, and End Results stage at diagnosis (424 participants); nonadenocarcinoma histology (52 participants); implausible date of death (2 participants); missing information regarding prediagnosis alcohol intake (216 participants); and missing prediagnosis smoking status (23 participants). In keeping with previous cancer survival analyses from this cohort, [19] [20] [21] [22] [23] [24] we decided a priori to exclude individuals with distant metastatic disease from the main analyses because the extremely poor 5-year relative survival in this group makes it unlikely that lifestyle factors would substantially affect long-term survival. Individuals with metastatic disease also are less likely to return a postdiagnosis survey. The impact of alcohol intake on survival among patients with metastatic disease was examined in a sensitivity analysis and reported separately.
After exclusions, 2458 participants (1370 men and 1088 women) were included in analyses of prediagnosis alcohol consumption, 1838 of whom were diagnosed with colon cancer (International Classification of Diseases for Oncology [ICD-O] codes C18.0 and C18.2-C18.9) and 620 participants were diagnosed with rectal cancer (ICD-O codes C19.9 and C20.9). According to the Surveillance, Epidemiology, and End Results summary stage categorization, 1238 participants were diagnosed with localized disease (malignant tumors limited to the colon or rectum) and 1220 participants were diagnosed with regional disease (tumors that spread to adjacent tissue or regional lymph nodes through the bowel wall). Those participants included and those excluded were comparable with regard to mean ages at baseline and at diagnosis as well as the percentages of men and self-reported white race/ethnicity.
Study Outcomes
Vital status and cause of death, when applicable, were identified for all participants through linkage to the NDI up to December 31, 2012. Cause of death was obtained for 99.3% of all known deaths in the cohort. The primary outcome in the current study was all-cause mortality. Secondary outcomes were mutually exclusive and included mortality specifically due to colorectal cancer (ICD Ninth Revision [ICD-9] codes 153 and 154 and ICD 10th revision [ICD-10] codes C18, C19, and C20), CVD (ICD-9 codes 390-459 and ICD-10 codes I00-I99), and all causes other than colorectal cancer or CVD. All cause of death information was defined from the singular underlying cause of death from NDI records.
Prediagnosis and Postdiagnosis Alcohol Intake
Alcohol intake was assessed at baseline and reassessed on subsequent follow-up questionnaires (1997, 1999, 2003, and 2007) . Data regarding prediagnosis alcohol intake were obtained from the last questionnaire returned before diagnosis; however, if the diagnosis occurred within 6 months of completion of the last questionnaire, the penultimate questionnaire returned before diagnosis was used because alcohol consumption might be influenced by symptoms during the period immediately preceding diagnosis. Postdiagnosis alcohol intake was evaluated using the first questionnaire completed after diagnosis. Of the 2458 participants included in the prediagnosis analysis, 1599 (65.1%) reported postdiagnosis alcohol information. Prediagnosis alcohol intake was reported a mean of 3.2 years before diagnosis whereas postdiagnosis alcohol intake was reported a mean of 1.9 years after diagnosis.
For all analyses, participants were categorized according to their alcohol intake status (never, former, or current). Current drinkers were categorized further according to the number of drinks per day (<2, 2 to < 3, and 3 for prediagnosis models and <2 and 2 for postdiagnosis models). Postdiagnosis former drinkers were categorized further based on the combination of their prediagnosis drinking status and their postdiagnosis drinking status (ie, former-former or current-former).
Statistical Analysis
Cox proportional hazards regression models were used to calculate RRs and 95% confidence intervals (95% CIs). The likelihood ratio test tested the proportional hazards assumption. Time since diagnosis was the underlying time axis for all analyses. For prediagnosis models, person-time started on the date of diagnosis. For postdiagnosis models, delayed-entry Cox models were used with follow-up starting on the date the participant returned the postdiagnosis questionnaire. 25 For all models, persontime ended at the date of death or the end of mortality follow-up (December 31, 2012).
All analyses were adjusted for age at diagnosis and tumor stage at diagnosis by stratifying within models, and we also a priori included sex in all models. In addition, we adjusted for prediagnosis or postdiagnosis smoking status in corresponding models (never smokers; former smokers who quit 30 years ago, 20 to < 30 years ago, or < 20 years ago; and current smokers who smoke <15 cigarettes/day or 15 cigarettes/day) because the RR estimates were changed by >10% with the inclusion of this variable. No other demographic, lifestyle, or clinical variable was found to change the RRs materially, but we chose to adjust for education, preexisting health conditions (chronic obstructive pulmonary disease, liver disease, and renal disease), and prediagnosis or postdiagnosis body mass index and physical activity in all models because of the previously reported associations between these variables and colorectal cancer survival in this cohort 22, 23 and the potential for correlation between these variables and alcohol.
In sensitivity analyses, the first 2 years of follow-up for prediagnosis and postdiagnosis models were excluded. We also excluded individuals whose postdiagnosis questionnaires were completed within 6 months of diagnosis. We repeated all analyses among individuals with metastatic disease. Furthermore, we examined prediagnosis and postdiagnosis consumption of specific types of alcohol (beer, wine, or liquor). All analyses were conducted using SAS statistical software (version 9.2; SAS Institute Inc, Cary, NC).
RESULTS
The mean age of the participants was 64.2 years at the time of cohort enrollment and 72.5 years at diagnosis; approximately 55.7% of the participants were men, and the majority reported their race as white. Compared with never drinkers, former and current alcohol drinkers were more likely to be men and current or former smokers, but were less likely to have a history of diabetes; former drinkers also were more likely to be diagnosed with colorectal cancer at an older age and to be physically active (Table 1) .
Among the 2458 individuals included in the prediagnosis analysis, 1156 deaths occurred during a mean follow-up of 8.3 years (standard deviation, 5.1 years; range, 2 days-20.1 years). As shown in Table 2 , prediagnosis drinking of <2 drinks per day was found to be associated with a statistically significantly lower risk of allcause mortality (RR, 0.86; 95% CI, 0.74-1.00). The inverse association was especially apparent for deaths from causes other than colorectal cancer or CVD (RR, 0.63; 95% CI, 0.50-0.80). Null associations were observed for prediagnosis alcohol intake and mortality specifically from colorectal cancer and CVD, separately. The results were not materially different after excluding the first 2 years of follow-up (data not shown). Null associations also were observed when we repeated the analysis for men and women diagnosed with metastatic disease (data not shown) or examined specific types of alcohol (see Supporting Information Table 1 ). In addition, we created an alternative exposure variable calculated as the "average alcohol intake" based on all prediagnosis questionnaires, but the results did not change materially (data not shown).
Among the 1599 men and women included in the postdiagnosis analysis, 732 deaths occurred during a mean follow-up of 8.2 years (standard deviation, 4.7 years; range, 20 days-15.6 years) (Table 3) . Overall, postdiagnosis alcohol intake was not found to be associated with mortality from all causes, colorectal cancer, CVD, and all other causes combined. However, we observed a statistically significantly higher risk of mortality from colorectal cancer specifically for individuals who were current drinkers before diagnosis but quit after diagnosis (RR, 1.81; 95% CI, 1.13-2.91). This pattern persisted in sensitivity analyses that excluded the first 2 years of follow-up and after excluding those participants who returned the postdiagnosis questionnaires within 6 months of diagnosis (data not shown). In addition, there was a suggestion of increased colorectal cancer-specific mortality with postdiagnosis current drinking (RR, 1.27 [95% CI, 0.87-1.86] for current drinking of <2 drinks/ day and RR, 1.44 [95% CI, 0.80-2.60] for current drinking of 2 drinks/day). This pattern persisted when we examined current alcohol consumption by type. However, the 95% CIs were wide and the results were not statistically significant due to small sample sizes (see Supporting Information Table 2 ).
DISCUSSION
In this large cohort study of men and women diagnosed with colorectal cancer, a prediagnosis alcohol intake of <2 drinks per day was found to be associated with a statistically significant lower risk of all-cause mortality, predominantly due to a lower risk of death from causes other than colorectal cancer or CVD. Postdiagnosis alcohol intake generally was not found to be associated with any of the mortality outcomes we examined, although the results of the current study do not preclude an association between higher levels of alcohol consumption and increased risks of colorectal cancer-specific mortality. To our knowledge, this is the first study to simultaneously examine both prediagnosis and postdiagnosis alcohol consumption in relation to colorectal cancer survival.
It is unclear why a prediagnosis alcohol intake of <2 drinks per day was associated with a slightly lower overall mortality from causes other than CVD or colorectal cancer in the current study. The leading causes of death in this category were respiratory system diseases, lung cancer, and nervous system diseases, which to our knowledge are not consistently inversely associated with alcohol consumption. However, similar inverse associations between light or moderate alcohol drinking and mortality have been reported previously among large cohorts of initially cancer-free participants. The Physicians' Health Study reported an inverse association between consuming <7 drinks per week and mortality from noncancer and nonOriginal Article Abbreviations: 95% CI, 95% confidence interval; CPS, Cancer Prevention Study; CVD, cardiovascular disease; RR, relative risk.
All RRs and 95% CIs were obtained from multivariable models adjusted for age at diagnosis, sex, tumor stage at diagnosis, smoking status, body mass index, physical activity, education, and preexisting diseases in 1982/1992 (chronic obstructive pulmonary disease, liver disease, or kidney disease). CVD causes, 26 and the CPS-II (with baseline in 1982) reported that consuming < 3 drinks per day was associated with a lower risk of mortality from causes other than CVD or other established alcohol-related diseases (eg, alcohol-related cancers and cirrhosis). 27 We also repeated our analysis among the entire CPS-II Nutrition Cohort of approximately 184,000 men and women and observed inverse associations with light or moderate alcohol consumption similar to those we observed among cohort participants diagnosed with colorectal cancer.
Residual confounding may at least partially account for the inverse association we observed between prediagnosis consumption of <2 drinks per day and mortality from causes other than colorectal cancer and CVD. Never drinkers may differ from light or moderate drinkers. In the current study, current moderate alcohol users were more likely to have a college degree (Table 1) . Although we adjusted for education, there may have been residual confounding from imperfect control for socioeconomic status and access to health care. In addition, individuals may choose to not drink alcohol because of preexisting health conditions. However, our analytical cohort excluded those with a history of any cancer before baseline and we adjusted for preexisting chronic conditions in the analysis.
We observed substantially increased colorectal cancer-specific mortality among participants who reported drinking on their prediagnosis questionnaire but not on their postdiagnosis questionnaire. Reverse causation is a likely explanation for this association; specifically, some patients might have stopped drinking after diagnosis as a result of colorectal cancer progression. In addition, those who quit drinking after diagnosis were more likely to have regional disease at the time of diagnosis (51%) compared with those who continued drinking (46%); however, we adjusted for tumor stage in all models.
We also observed some suggestion of increased colorectal cancer-specific mortality among participants who continued to drink alcohol after diagnosis, particularly at higher levels. Although these associations were not statistically significant and could well be due to chance, it is biologically plausible that alcohol could facilitate distant metastasis from cancer cells that escaped the colon at the time of treatment. 28 In addition, we may have underestimated the RR for postdiagnosis alcohol use if some patients discontinued drinking after diagnosis as a result of their disease progression, a possibility that is consistent with the results noted among former drinkers.
Four previous studies examined the association between alcohol consumption and colorectal cancer-specific mortality. 9, 10, 12, 13 In the Nurses' Health Study, which to the best of our knowledge is the only study that examined postdiagnosis alcohol consumption, no association was observed with mortality from colorectal cancer. However, the highest category examined was only >15 g alcohol per day (approximately 1.5 drinks), possibly because few women in the study cohort drank in higher amounts. 12 In 3 studies that examined prediagnosis alcohol use, 2 studies observed lower colorectal cancer-specific mortality among light or moderate drinkers, but not heavy drinkers, 9, 13 whereas one study observed largely null associations. 10 Major strengths of the current study include its large sample size (especially for the prediagnosis analysis), prospective design, and detailed prediagnosis and postdiagnosis questionnaire information, which enabled us to perform what to the best of our knowledge is the first study of both prediagnosis and postdiagnosis alcohol intake in relation to colorectal cancer survival. Limitations include the potential for residual confounding by correlates of alcohol use. In addition, because we lacked data regarding treatment side effects and cancer recurrence or other indicators of postdiagnosis illness, we were unable to account for these factors in the analysis.
In the current study, we observed largely null results for the associations between prediagnosis and postdiagnosis alcohol consumption and mortality among individuals with invasive, nonmetastatic colorectal cancer. However, there was some suggestion of an association between postdiagnosis drinking, especially in higher amounts, and a higher risk of mortality specifically due to colorectal cancer, although this association was not found to be statistically significant. The association between postdiagnosis alcohol use and colorectal cancer-specific mortality warrants investigation in future studies of survivors of nonmetastatic colorectal cancer, ideally in populations in which moderate to heavy consumption of alcohol is common.
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